Accuray Incorporated (0H8I.L)
USD 1.91
(-2.54%)
USD 1.91
(-2.54%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 9 Million USD | -6.24% |
| 2022 | 8.37 Million USD | -29.66% |
| 2021 | 13.66 Million USD | -52.27% |
| 2020 | 28.62 Million USD | 35.15% |
| 2019 | 20.08 Million USD | 68.44% |
| 2018 | 11.07 Million USD | 111.86% |
| 2017 | 5.93 Million USD | -27.42% |
| 2016 | 8.17 Million USD | -58.75% |
| 2015 | 12.58 Million USD | 361.66% |
| 2014 | -7.57 Million USD | -413.06% |
| 2013 | 2.42 Million USD | 105.26% |
| 2012 | -57.84 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 FY | - USD | -33.3% |
| 2023 Q2 | -2.41 Million USD | -169.8% |
| 2023 Q3 | -2.96 Million USD | -22.46% |
| 2023 Q4 | 8.32 Million USD | 381.12% |
| 2023 Q1 | 3.46 Million USD | 441.25% |
| 2022 Q4 | 640 Thousand USD | -84.83% |
| 2022 FY | - USD | -29.66% |
| 2022 Q3 | 4.21 Million USD | 9.41% |
| 2022 Q2 | 3.85 Million USD | 483.3% |
| 2022 Q1 | -1 Million USD | -130.27% |
| 2021 Q1 | 3.87 Million USD | -31.37% |
| 2021 Q2 | 5.44 Million USD | 40.56% |
| 2021 Q3 | 1.14 Million USD | -78.9% |
| 2021 Q4 | 3.32 Million USD | 189.46% |
| 2021 FY | - USD | -52.27% |
| 2020 Q3 | 6 Million USD | -39.11% |
| 2020 Q1 | 7.12 Million USD | -0.82% |
| 2020 Q4 | 5.64 Million USD | -6.02% |
| 2020 Q2 | 9.85 Million USD | 38.27% |
| 2020 FY | - USD | 35.15% |
| 2019 Q4 | 7.18 Million USD | -26.95% |
| 2019 Q1 | -2.41 Million USD | -144.22% |
| 2019 Q2 | 5.47 Million USD | 326.5% |
| 2019 FY | - USD | 68.44% |
| 2019 Q3 | 9.83 Million USD | 79.85% |
| 2018 Q4 | 5.46 Million USD | 13.89% |
| 2018 Q3 | 4.79 Million USD | 307.39% |
| 2018 Q2 | 1.17 Million USD | 145.99% |
| 2018 Q1 | -2.55 Million USD | -147.06% |
| 2018 FY | - USD | 111.86% |
| 2017 Q1 | 462 Thousand USD | -91.36% |
| 2017 FY | - USD | -27.42% |
| 2017 Q4 | 5.43 Million USD | 477.38% |
| 2017 Q3 | -1.44 Million USD | -197.63% |
| 2017 Q2 | 1.47 Million USD | 219.48% |
| 2016 Q4 | 5.34 Million USD | 311.23% |
| 2016 Q3 | 1.3 Million USD | 130.97% |
| 2016 Q2 | -4.19 Million USD | -121.88% |
| 2016 Q1 | -1.89 Million USD | -514.29% |
| 2016 FY | - USD | -58.75% |
| 2015 Q4 | -308 Thousand USD | -103.84% |
| 2015 Q1 | -4.67 Million USD | -382.98% |
| 2015 Q3 | 8.02 Million USD | 237.47% |
| 2015 Q2 | 2.37 Million USD | 150.9% |
| 2015 FY | - USD | 361.66% |
| 2014 FY | - USD | -413.06% |
| 2014 Q4 | 1.65 Million USD | -59.49% |
| 2014 Q1 | -12.29 Million USD | -3602.56% |
| 2014 Q3 | 4.07 Million USD | 769.29% |
| 2014 Q2 | -609 Thousand USD | 95.05% |
| 2013 Q1 | -6.83 Million USD | -0.47% |
| 2013 Q3 | 4.49 Million USD | 1.88% |
| 2013 Q4 | 351 Thousand USD | -92.19% |
| 2013 FY | - USD | 105.26% |
| 2013 Q2 | 4.41 Million USD | 164.52% |
| 2012 Q4 | -6.8 Million USD | 52.1% |
| 2012 Q3 | -14.21 Million USD | -15.78% |
| 2012 Q2 | -12.27 Million USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Phreesia, Inc. | -102.94 Million USD | 108.751% |
| Align Technology, Inc. | 799.03 Million USD | 98.873% |
| Elevance Health Inc. | 10.49 Billion USD | 99.914% |
| AxoGen, Inc. | -13.32 Million USD | 167.595% |
| Boston Scientific Corporation | 3.61 Billion USD | 99.751% |
| CVS Health Corporation | 18.17 Billion USD | 99.95% |
| Cardinal Health, Inc. | 1.97 Billion USD | 99.545% |
| Centene Corporation | -463 Million USD | 101.946% |
| DaVita Inc. | 2.34 Billion USD | 99.616% |
| HCA Healthcare, Inc. | 12.72 Billion USD | 99.929% |
| Hologic, Inc. | 1.29 Billion USD | 99.305% |
| Humana Inc. | -561 Million USD | 101.606% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 99.26% |
| Laboratory Corporation of America Holdings | 1.34 Billion USD | 99.332% |
| Masimo Corporation | 236.7 Million USD | 96.194% |
| McKesson Corporation | 4.66 Billion USD | 99.807% |
| Patterson Companies, Inc. | 374.75 Million USD | 97.596% |
| Quest Diagnostics Incorporated | 1.73 Billion USD | 99.48% |
| ResMed Inc. | 1.6 Billion USD | 99.437% |
| Henry Schein, Inc. | 943 Million USD | 99.045% |
| Teladoc Health, Inc. | 153.99 Million USD | 94.15% |
| Universal Health Services, Inc. | 1.74 Billion USD | 99.483% |
| Veeva Systems Inc. | 429.33 Million USD | 97.902% |
| Baxter International Inc. | 2.77 Billion USD | 99.675% |
| Becton, Dickinson and Company | 4.27 Billion USD | 99.789% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 99.624% |
| Danaher Corporation | 7.49 Billion USD | 99.88% |
| Stryker Corporation | 5.16 Billion USD | 99.825% |
| Medtronic plc | 9.05 Billion USD | 99.901% |